Aortic Aneurysm Stent Grafts Market Summary

• The aortic aneurysm stent grafts market size is estimated at USD 3.85 billion in 2025 and is projected to reach USD 7.70 billion by 2034. Growth is anchored in the rising global burden of aortic aneurysms, the accelerating shift from open surgical repair to endovascular procedures, and continued innovation in fenestrated and branched graft technology.
• The global Aortic Aneurysm Stent Grafts market is growing at a CAGR of 8.3% during the forecast period from 2026 to 2034.
• By product type, the abdominal aortic aneurysm (AAA) stent grafts segment dominated the Aortic Aneurysm Stent Grafts market with a 61% share in 2025.
• By procedure type, the Endovascular Aneurysm Repair (EVAR) segment dominated the Aortic Aneurysm Stent Grafts market with a 58% share in 2025.
• By graft design, the standard stent grafts segment dominated the Aortic Aneurysm Stent Grafts market with a 66% share in 2025.
• By material, the polyester (Dacron)-based stent grafts segment dominated the Aortic Aneurysm Stent Grafts market with a 52% share in 2025.
• By fixation type, the infrarenal fixation segment dominated the Aortic Aneurysm Stent Grafts market with a 63% share in 2025.
• By end user, the hospitals segment dominated the Aortic Aneurysm Stent Grafts market with a 69% share in 2025.
• North America dominated the global aortic aneurysm stent grafts market revenue with a 44% share in 2025, representing the highest regional market share globally.

An aortic aneurysm stent graft is a fabric-covered metal mesh implant delivered through a catheter-based, minimally invasive procedure to reinforce a weakened, ballooning section of the aorta and prevent life-threatening rupture. The device is deployed inside the diseased segment of the aorta, where it excludes the aneurysm sac from systemic blood pressure while providing a durable conduit for blood flow. Because open surgical repair carries substantially higher perioperative morbidity and mortality, hospitals and specialty cardiovascular centers increasingly favor endovascular approaches, driving sustained demand for stent graft systems.

The market is organized by product type across abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA) stent grafts; by procedure type across Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aneurysm Repair (TEVAR), Fenestrated Endovascular Aneurysm Repair (FEVAR), and Branched Endovascular Aneurysm Repair (BEVAR); by graft design across standard, fenestrated, and branched configurations; by material across polyester (Dacron)-based, expanded polytetrafluoroethylene (ePTFE)-based, and hybrid-material grafts; and by fixation type across infrarenal and suprarenal fixation. Driven by an aging global population, expanding aneurysm-screening programs, and continuous device innovation supporting increasingly complex aortic anatomies, aortic aneurysm stent grafts have become the standard of care across the majority of elective and emergent aneurysm repairs worldwide.

Aortic Aneurysm Stent Grafts Market Key Growth Drivers

• The rising global prevalence of abdominal and thoracic aortic aneurysms, driven by an aging population and higher rates of hypertension, atherosclerosis, and smoking, is expanding the eligible patient pool for stent graft repair.
• The continued clinical shift from open surgical repair to minimally invasive EVAR and TEVAR is accelerating stent graft adoption, supported by lower perioperative mortality, shorter hospital stays, and faster recovery.
• Expanding aneurysm-screening programs, including Czechia's February 2025 national pilot for men aged 65-67 and established Medicare-covered ultrasound screening in the United States, are improving early detection and driving elective repair volumes.
• Technological advancements, including low-profile delivery systems, polymer-sealing endografts, and fenestrated and branched configurations, are expanding the population of patients eligible for endovascular repair, including those with hostile neck anatomy.
• Regulatory approvals and label expansions, including Medtronic's October 2025 FDA labeling update removing the ruptured AAA treatment warning from the Endurant stent graft system, are reinforcing physician confidence and broadening indicated use.
• Growing adoption of complex FEVAR and BEVAR procedures for juxtarenal, pararenal, and thoracoabdominal aneurysms is expanding the addressable market beyond standard infrarenal anatomy.
• Rising capital investment and strategic activity among device manufacturers, including new product launches and geographic expansions, are broadening access to advanced stent graft technology across emerging markets.

Key Companies in Aortic Aneurysm Stent Grafts Market

The competitive landscape is led by the following active device manufacturers:

• Medtronic
• Terumo
• Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (MicroPort Scientific Corporation)
• Cook
• Cordis
• JOTEC GmbH
• W. L. Gore & Associates, Inc.
• Endologix LLC
• Lombard Medical
• LifeTech Scientific, and others

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Aortic Aneurysm Stent Grafts Market Size

The following snapshot summarizes the principal report metrics for the aortic aneurysm stent grafts market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Aortic Aneurysm Stent Grafts Market

Aortic Aneurysm Stent Grafts Market Drivers

• Rising Global Prevalence of Aortic Aneurysms and an Aging Population: The most fundamental driver of the aortic aneurysm stent grafts market is the rising global prevalence of abdominal and thoracic aortic aneurysms, a disease strongly correlated with age. Aneurysm risk rises sharply after age 65, and the disease disproportionately affects men with a history of smoking, hypertension, and atherosclerosis. As life expectancy increases across developed and emerging economies alike, the pool of patients at risk of aneurysm formation and rupture continues to expand. Aortic aneurysms are frequently asymptomatic until rupture, which carries a mortality rate exceeding 80%, making timely detection and repair a clinical priority. This growing, aging, at-risk population directly enlarges the addressable base for elective and emergent stent graft procedures, anchoring durable market growth through 2034.
• Accelerating Shift from Open Surgical Repair to Endovascular Procedures: A structural shift toward minimally invasive treatment is a central growth engine for the market. Endovascular aneurysm repair delivers a catheter-based stent graft through the femoral arteries under imaging guidance, avoiding the large abdominal or thoracic incisions required by open surgical repair. Clinical evidence consistently shows endovascular repair carries substantially lower perioperative mortality than open surgery, alongside shorter hospital stays and faster return to normal activity, particularly important for the elderly and high-risk patients who make up the majority of the aneurysm population. In the United States, the large majority of abdominal aortic aneurysm procedures are now performed endovascularly rather than through open surgery. As hospitals and specialty cardiovascular centers continue to expand hybrid operating room capacity and physician training, the endovascular share of aneurysm repair volume is expected to keep rising, directly enlarging stent graft demand across the forecast period.
• Expanding Aneurysm Screening Programs and Early Detection: Government and health-system investment in aneurysm-screening programs is expanding the pipeline of diagnosed, treatable patients. In February 2025, Czechia launched a national pilot abdominal aortic aneurysm screening program for men aged 65 to 67, aiming to detect AAAs early and prevent up to 100 deaths annually, following the precedent of established ultrasound-screening programs in the United States and the United Kingdom. Because most aneurysms are silent until rupture, systematic screening converts previously undiagnosed disease into a scheduled, elective treatment population, which is both safer for patients and more predictable for healthcare systems. As additional countries adopt or expand screening protocols, the resulting increase in early-stage diagnoses is expected to steadily grow the pool of patients eligible for elective EVAR and TEVAR, reinforcing long-term stent graft procedure volumes.
• Continuous Technological Advancement Expanding Treatable Anatomies: Device innovation is directly expanding the population of patients eligible for endovascular repair. Manufacturers are introducing lower-profile delivery systems that reduce access-vessel complications, polymer-sealing endografts that improve proximal sealing and reduce Type I endoleaks, and fenestrated and branched configurations that accommodate short necks, tortuous iliac arteries, and visceral-branch involvement, anatomies once considered inoperable by endovascular means. Clinical data presented at vascular conferences in 2024 demonstrated meaningful reductions in Type I endoleak rates with newer polymer-sealed designs compared to legacy grafts. As these advanced devices gain regulatory approval and clinical adoption, they convert patients who previously required open surgery, or who were deemed unsuitable for any repair, into candidates for endovascular treatment, broadening the addressable market for premium, higher-value stent graft systems.
• Regulatory Approvals and Label Expansions Broadening Indicated Use: A steady cadence of regulatory approvals and label expansions is increasing both procedure eligibility and physician confidence. In October 2025, Medtronic received FDA labeling approval for its Endurant stent graft system that added ruptured abdominal aortic aneurysm clinical evidence and removed the prior rAAA treatment warning, making it the first stent graft system with this labeling update and enabling more confident emergency use. In January 2025, W. L. Gore & Associates received FDA approval for the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, an off-the-shelf solution for complex aneurysms affecting the visceral aorta. Terumo Aortic has likewise expanded the approved dissection and transection indications for its RELAY Pro stent-graft system. Each approval and label expansion creates durable, recurring demand by widening the population of patients who can be treated on-label with a given device, reinforcing market growth across the forecast period.
• Growing Adoption of Complex FEVAR and BEVAR Procedures: Fenestrated and branched endovascular repair is emerging as a critical growth segment as physicians extend endovascular treatment to juxtarenal, pararenal, and thoracoabdominal aneurysms that fall outside standard infrarenal anatomy. Products such as Cook Medical's Zenith Fenestrated+ platform and a growing pipeline of branched devices are enabling treatment of increasingly complex aortic pathology without open surgery. As vascular surgeons gain experience and training with these advanced techniques, and as more centers develop dedicated complex aortic programs, FEVAR and BEVAR procedure volumes are expected to grow faster than the overall market, expanding demand for premium, higher-priced graft systems.

Aortic Aneurysm Stent Grafts Market Restraints

Despite strong momentum, the aortic aneurysm stent grafts market faces material constraints. The high cost of advanced stent graft systems and the associated endovascular procedure, including imaging infrastructure and hybrid operating rooms, limits adoption in cost-sensitive and lower-reimbursement healthcare systems. The risk of endoleaks, graft migration, and the need for lifelong surveillance imaging and potential reintervention raise long-term costs and create durability concerns relative to open surgical repair in younger, lower-risk patients. Complex aortic anatomies, including short or angulated necks, small or heavily calcified access vessels, and extensive visceral-branch involvement, continue to limit endovascular eligibility for a meaningful share of patients despite advances in fenestrated and branched technology. A shortage of vascular surgeons trained in complex endovascular techniques constrains procedure volume growth in several regions, while reimbursement for premium fenestrated, branched, and polymer-sealed devices remains uneven across geographies. Open surgical repair continues to be favored in select younger and low-surgical-risk patients due to superior long-term durability data, tempering endovascular penetration at the margin. Together, these cost, durability, anatomical, workforce, and reimbursement barriers moderate the pace of growth, even as the underlying drivers of an aging population, screening expansion, and technological innovation remain firmly intact.

Aortic Aneurysm Stent Grafts Market Segment Analysis

The Aortic Aneurysm Stent Grafts by Product Type (Abdominal Aortic Aneurysm (AAA) Stent Grafts, Thoracic Aortic Aneurysm (TAA) Stent Grafts), Procedure Type (Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aneurysm Repair (TEVAR), Fenestrated Endovascular Aneurysm Repair (FEVAR), Branched Endovascular Aneurysm Repair (BEVAR)), Graft Design (Standard Stent Grafts, Fenestrated Stent Grafts, Branched Stent Grafts), Material (Polyester (Dacron)-Based Stent Grafts, Expanded Polytetrafluoroethylene (ePTFE)-Based Stent Grafts, Hybrid Materials), Fixation Type (Infrarenal Fixation, Suprarenal Fixation), End User (Hospitals, Specialty Cardiovascular Centers, Ambulatory Surgical Centers (ASCs)), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

By Type

Dominant Subsegment: Abdominal Aortic Aneurysm (AAA) Stent Grafts. The Abdominal Aortic Aneurysm (AAA) Stent Grafts category is expected to dominate the market.

Dominant: Abdominal Aortic Aneurysm (AAA) Stent Grafts ~ 61%

The abdominal aortic aneurysm (AAA) stent grafts segment accounted for 61% of the Aortic Aneurysm Stent Grafts market in 2025. AAA stent grafts are the leading product type because abdominal aortic aneurysms are substantially more prevalent than thoracic aneurysms, particularly among the aging, hypertensive, and smoking-history populations most at risk, and because EVAR for infrarenal AAA is the most mature, widely practiced, and best-reimbursed endovascular aortic procedure. Landmark clinical trials have demonstrated durable reductions in aneurysm-related mortality with AAA endovascular repair, and decades of clinical experience, favorable reimbursement policies, and broad physician familiarity reinforce widespread adoption. Leading devices in this segment, including Medtronic's Endurant family and W. L. Gore's Excluder AAA Device Family, benefit from extensive long-term outcomes data. While thoracic aortic aneurysm stent grafts are growing faster, propelled by rising TEVAR adoption and expanding indications for aortic dissection and transection, the sheer prevalence and procedural maturity of AAA repair secure the segment's leadership across the forecast period.

By Procedure Type

Dominant Subsegment: Endovascular Aneurysm Repair (EVAR). The Endovascular Aneurysm Repair (EVAR) category is expected to dominate the market.

Dominant: Endovascular Aneurysm Repair (EVAR) ~ 58%

The Endovascular Aneurysm Repair (EVAR) segment accounted for 58% of the Aortic Aneurysm Stent Grafts market in 2025. EVAR is the leading procedure type because it is the standard first-line treatment for anatomically suitable infrarenal abdominal aortic aneurysms, offering markedly lower perioperative mortality than open surgical repair alongside shorter hospital stays and faster recovery. The high prevalence of AAA relative to other aortic pathologies, combined with decades of accumulated clinical evidence, established reimbursement pathways, and broad training among vascular and interventional specialists, sustains very high EVAR procedure volumes globally. TEVAR is expanding quickly as thoracic aneurysm diagnosis rises and devices such as Terumo's RELAY Pro and Medtronic's thoracic portfolio gain expanded dissection and transection indications, while FEVAR and BEVAR are the fastest-growing procedure types as physicians extend endovascular treatment to complex juxtarenal, pararenal, and thoracoabdominal anatomies. Nonetheless, the scale and procedural maturity of standard infrarenal EVAR secure its leadership across the forecast period.

By Graft Design

Dominant Subsegment: Standard Stent Grafts. The Standard Stent Grafts category is expected to dominate the market.

Dominant: Standard Stent Grafts ~ 66%

The standard stent grafts segment accounted for 66% of the Aortic Aneurysm Stent Grafts market in 2025. Standard stent grafts lead the graft-design segment because they address the majority of straightforward infrarenal AAA and uncomplicated thoracic aneurysm anatomies, which represent the largest share of the treatable patient population, and because they carry lower unit costs, simpler procedural planning, and broader inventory availability than custom or complex designs. Hospitals and specialty centers favor standard configurations for routine elective and emergent cases given their extensive track record and rapid availability, particularly in time-sensitive ruptured aneurysm presentations. Fenestrated and branched stent grafts are growing markedly faster, supported by devices such as Cook Medical's Zenith Fenestrated+ platform and MicroPort Endovastec's Castor and Minos systems, as physicians increasingly treat complex juxtarenal and thoracoabdominal anatomies endovascularly. Even so, the breadth of standard anatomical indications keeps standard stent grafts the dominant graft design across the forecast period.

By Material

Dominant Subsegment: Polyester (Dacron)-Based Stent Grafts. The Polyester (Dacron)-Based Stent Grafts category is expected to dominate the market.

Dominant: Polyester (Dacron)-Based Stent Grafts ~ 52%

The polyester (Dacron)-based stent grafts segment accounted for 52% of the Aortic Aneurysm Stent Grafts market in 2025. Polyester-based grafts lead the material segment because woven or knitted polyester fabric offers a well-established balance of durability, biocompatibility, and manufacturability that has anchored aortic graft design for decades, supported by an extensive long-term clinical safety record across both AAA and TAA repair. Its lower porosity variants provide reliable sealing while remaining cost-effective to manufacture at scale, sustaining its use across the large base of standard stent graft devices. Expanded polytetrafluoroethylene (ePTFE)-based grafts, used in platforms such as W. L. Gore's Excluder family, are valued for their low porosity and favorable handling characteristics and continue to gain share, while hybrid-material designs combining both fabrics are emerging in next-generation, low-profile devices aimed at improving conformability and sealing performance in complex anatomies. Nonetheless, the scale and cost advantages of polyester-based construction secure its leadership across the forecast period.

By Fixation Type

Dominant Subsegment: Infrarenal Fixation. The Infrarenal Fixation category is expected to dominate the market.

Dominant: Infrarenal Fixation ~ 63%

The infrarenal fixation segment accounted for 63% of the Aortic Aneurysm Stent Grafts market in 2025. Infrarenal fixation leads the fixation-type segment because it is suitable for the large majority of standard AAA anatomies with an adequate infrarenal neck, avoids crossing the renal arteries, and is associated with a well-established long-term safety profile across widely used platforms. Its simpler deployment and broad anatomical applicability make it the default choice for routine elective and emergent AAA repair. Suprarenal fixation, which anchors the stent graft above the renal arteries to improve resistance to migration in patients with shorter or more angulated necks, is growing steadily as physicians treat more challenging anatomies and as devices such as Medtronic's Endurant family, which combine a suprarenal fixation option, gain broader adoption in complex cases. Nonetheless, the prevalence of favorable infrarenal anatomy in the overall AAA population keeps infrarenal fixation the dominant approach across the forecast period.

By End User

Dominant Subsegment: Hospitals. The Hospitals category is expected to dominate the market.

Dominant: Hospitals ~ 69%

The hospitals segment accounted for 69% of the Aortic Aneurysm Stent Grafts market in 2025. Hospitals are the leading end user because they house the hybrid operating rooms, advanced imaging infrastructure, and multidisciplinary vascular surgery teams required for complex EVAR, TEVAR, FEVAR, and BEVAR procedures, and because they remain the default setting for emergent ruptured aneurysm repair. The availability of experienced vascular surgeons, anesthesiology support, and intensive care capacity ensures hospitals are preferred for both routine and high-risk cases. Specialty cardiovascular centers are expanding their share as dedicated aortic programs proliferate and build deep procedural expertise, while ambulatory surgical centers are the fastest-growing end-user segment as advances in local anesthesia, percutaneous vascular closure devices, and enhanced recovery protocols enable selected low-risk, anatomically straightforward EVAR cases to migrate to outpatient settings. Nonetheless, the complexity and emergency-readiness requirements of aneurysm repair keep hospitals the dominant end-user segment across the forecast period.

Aortic Aneurysm Stent Grafts Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 44% (Largest)

North America accounted for 44% of the global Aortic Aneurysm Stent Grafts market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high and growing prevalence of aortic aneurysms among an aging population, an established Medicare-covered ultrasound screening pathway, broad reimbursement for both standard and complex endovascular repair, and the concentrated presence of leading device manufacturers including Medtronic, Cook Medical, W. L. Gore & Associates, and Endologix. North America hosts extensive hybrid operating room infrastructure and a deep base of vascular surgeons trained in EVAR, TEVAR, FEVAR, and BEVAR, supporting high procedure volumes across both elective and emergent settings. Continued regulatory approvals, including Medtronic's 2025 Endurant rAAA labeling update and Gore's Thoracoabdominal Branch Endoprosthesis approval, reinforce physician confidence and expand indicated use. Strong reimbursement, mature screening infrastructure, and proximity to leading manufacturers anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Aortic Aneurysm Stent Grafts market. The region's elevated CAGR is driven by rising cardiovascular disease burden, rapid expansion of hospital and vascular surgery infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's Volume-Based Procurement program is broadening access to domestically produced endografts from manufacturers such as Shanghai MicroPort Endovascular MedTech, India is scaling national aneurysm screening and awareness initiatives, and Japan continues to expand adoption of advanced TEVAR and fenestrated technology. Regional device makers, including MicroPort Endovastec and LifeTech Scientific, are broadening their product portfolios and securing regulatory approvals across Latin America and Southeast Asia in addition to their home markets. The combination of rising disease prevalence, expanding hospital capacity, and growing domestic manufacturing capability positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Aortic Aneurysm Stent Grafts Regional Commentary

North America

North America accounted for 44% of the global aortic aneurysm stent grafts market revenue in 2025. The United States dominates on the strength of its vascular surgery infrastructure, established screening pathway, favorable reimbursement, and the concentrated presence of leading device manufacturers, while continued regulatory approvals and label expansions reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by strong national health systems, established CE-marking pathways, and growing adoption of complex FEVAR and BEVAR procedures. Screening initiatives such as Czechia's 2025 national AAA pilot, alongside device innovation from JOTEC GmbH and other regional manufacturers, reinforce the region's role in advanced aortic repair across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease prevalence, expanding hospital infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's Volume-Based Procurement program, India's expanding screening and treatment access, and the growth of regional manufacturers such as MicroPort Endovastec and LifeTech Scientific are accelerating adoption across the region.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding hospital and vascular surgery infrastructure, rising diagnosis of aortic aneurysms, and regulatory approvals extending device availability into markets such as Brazil and Argentina are gradually broadening access, while international partnerships support continued build-out of regional treatment capacity.

Aortic Aneurysm Stent Grafts Market Competitive Landscape

The Aortic Aneurysm Stent Grafts market is classified as Moderately Concentrated. A group of established multinational players with broad AAA and TAA portfolios and long-term clinical data, including Medtronic, W. L. Gore & Associates, Cook, and Terumo, anchors the top tier, while specialized and fast-scaling providers such as Shanghai MicroPort Endovascular MedTech, LifeTech Scientific, Cordis, JOTEC GmbH, Endologix LLC, and Lombard Medical compete through targeted anatomical indications, regional manufacturing, and complex-anatomy device innovation, increasing competition in the fastest-growing FEVAR and BEVAR segments.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with established multinational leaders and a fast-growing field of specialized complex-anatomy device makers.
• Leading players: Medtronic, W. L. Gore & Associates, Cook, and Terumo anchor the top tier through broad AAA and TAA portfolios and extensive long-term clinical evidence.
• Geographic reach: Leaders operate global manufacturing and distribution networks; MicroPort Endovastec has extended device approvals across Latin America and Southeast Asia in addition to its core Asia-Pacific base.
• Product portfolio strength: Top players offer end-to-end portfolios spanning standard, fenestrated, and branched grafts across both AAA and TAA indications, supported by low-profile delivery systems.
• Clinical evidence depth: Long-term outcomes data, including decade-plus registries for platforms such as Medtronic's Endurant and Gore's Excluder families, is a decisive advantage in physician adoption.
• Regulatory momentum: Label expansions and approvals, such as Medtronic's 2025 rAAA labeling update and Gore's Thoracoabdominal Branch Endoprosthesis approval, extend indicated use and reinforce leadership.
• Geographic expansion: Active regulatory filings and launches in emerging markets, including MicroPort Endovascular's 2025 Talos Thoracic Stent Graft approvals in Brazil and Argentina, extend reach.
• Manufacturing capabilities: Precision nitinol and polyester/ePTFE fabric fabrication, low-profile delivery-system engineering, and rigorous durability testing are key competitive moats.
• Innovation focus: Fenestrated and branched graft expansion, polymer-sealing technology, ultra-low-profile delivery systems, and off-the-shelf solutions for complex thoracoabdominal anatomy.

Aortic Aneurysm Stent Grafts Market Recent Developmental Activities

• In October 2025, Medtronic received FDA labeling approval for its Endurant stent graft system, adding ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removing the rAAA treatment warning, becoming the first company to achieve this labeling update.
• In April 2025, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. obtained regulatory approvals for its Talos Thoracic Stent Graft System in Brazil and Argentina, expanding availability of its advanced thoracic aortic repair technology.
• In January 2025, W. L. Gore & Associates, Inc. received FDA approval for the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, an off-the-shelf endovascular solution for complex aneurysms involving the visceral aorta.
• In 2025, Terumo expanded the approved dissection and transection indications for its RELAY Pro stent-graft system in the United States, broadening the clinical scope of its thoracic aortic platform.
• In August 2024, Terumo launched the TREO Registered Stent-Graft System in India, expanding access to its abdominal aortic aneurysm repair technology in a key emerging market.
• In January 2024, Cook treated the first patient in the clinical study of the Zenith Fenestrated+ Endovascular Graft, advancing its complex-anatomy fenestrated repair platform.
• In September 2023, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. completed the first clinical implantation of its Minos Stent Graft System in Azerbaijan, extending its abdominal aortic device to new international markets.
• In September 2023, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. expanded its endovascular aortic intervention product line with FDA clearance in Thailand for the Castor Branched, Minos Abdominal, and Hercules LP Stent-Graft Systems.
• In 2023, LifeTech Scientific continued to expand real-world clinical evidence for its Ankura AAA stent graft platform through independent European outcomes studies of infrarenal aneurysm repair.
• In 2023, JOTEC GmbH continued to broaden its E-nya and E-liac stent graft portfolios to support increasingly complex iliac and infrarenal anatomies as part of its aortic and peripheral device strategy.

Aortic Aneurysm Stent Grafts Market Segmentation

• Aortic Aneurysm Stent Grafts Market by Product Type
  • Abdominal Aortic Aneurysm (AAA) Stent Grafts
  • Thoracic Aortic Aneurysm (TAA) Stent Grafts
• Aortic Aneurysm Stent Grafts Market by Procedure Type
  • Endovascular Aneurysm Repair (EVAR)
  • Thoracic Endovascular Aneurysm Repair (TEVAR)
  • Fenestrated Endovascular Aneurysm Repair (FEVAR)
  • Branched Endovascular Aneurysm Repair (BEVAR)
• Aortic Aneurysm Stent Grafts Market by Graft Design
  • Standard Stent Grafts
  • Fenestrated Stent Grafts
  • Branched Stent Grafts
• Aortic Aneurysm Stent Grafts Market by Material
  • Polyester (Dacron)-Based Stent Grafts
  • Expanded Polytetrafluoroethylene (ePTFE)-Based Stent Grafts
  • Hybrid Materials
• Aortic Aneurysm Stent Grafts Market by Fixation Type
  • Infrarenal Fixation
  • Suprarenal Fixation
• Aortic Aneurysm Stent Grafts Market by End User
  • Hospitals
  • Specialty Cardiovascular Centers
  • Ambulatory Surgical Centers (ASCs)

Aortic Aneurysm Stent Grafts Market by Geography

• North America Aortic Aneurysm Stent Grafts Market
  • United States Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Canada Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Mexico Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
• Europe Aortic Aneurysm Stent Grafts Market
  • Germany Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • United Kingdom Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • France Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Italy Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Spain Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Rest of Europe Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
• Asia-Pacific Aortic Aneurysm Stent Grafts Market
  • China Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Japan Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • India Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Australia Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • South Korea Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
• Rest of the World (RoW) Aortic Aneurysm Stent Grafts Market
  • Middle East Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • Africa Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)
  • South America Aortic Aneurysm Stent Grafts Market Size in USD million (2023-2034)

Aortic Aneurysm Stent Grafts Market Recent Industry Trends and Milestones (2023-2026):

Aortic Aneurysm Stent Grafts Market Startup Funding and Investment Trends

The Aortic Aneurysm Stent Grafts market is dominated by large strategic players such as Medtronic, Gore, Cook Medical, Terumo Aortic, Endologix, Bentley Innomed, and Artivion. Consequently, venture capital funding activity is relatively limited compared with other cardiovascular sectors. Most investments have been directed toward startups developing next-generation branched, fenestrated, low-profile, and off-the-shelf endovascular stent graft technologies for complex aortic aneurysms and aortic arch repair.

Key Takeaways from the Aortic Aneurysm Stent Grafts Market Report Study

• Market size analysis for the current aortic aneurysm stent grafts market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global aortic aneurysm stent grafts market.
• Various opportunities available for competitors in the aortic aneurysm stent grafts market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current aortic aneurysm stent grafts market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for aortic aneurysm stent grafts market growth in the future?

Target audience who can benefit from this Aortic Aneurysm Stent Grafts market report study

• Aortic aneurysm stent grafts product providers
• Research organizations and consulting companies
• Aortic aneurysm stent grafts-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in aortic aneurysm stent grafts
• Various end-users who want to know more about the aortic aneurysm stent grafts market, and the latest technological developments in the aortic aneurysm stent grafts market.

Frequently Asked Questions

Q1. What is the growth rate of the aortic aneurysm stent grafts market?

The aortic aneurysm stent grafts market is projected to expand at a CAGR of 8.3% during the forecast period from 2026-2034.

Q2. What is the market size of the aortic aneurysm stent grafts market?

The aortic aneurysm stent grafts market size is estimated at USD 3.85 billion in 2025 and is projected to reach USD 7.70 billion by 2034.siz

Q3. Which region dominates the aortic aneurysm stent grafts market?

North America dominated the aortic aneurysm stent grafts market with a 44% share of global revenue in 2025, supported by a high prevalence of aortic aneurysms, an established national screening pathway, broad reimbursement for endovascular repair, and the concentrated presence of leading device manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the aortic aneurysm stent grafts market?

The principal drivers are the rising global prevalence of aortic aneurysms among an aging population; the accelerating clinical shift from open surgical repair to minimally invasive EVAR and TEVAR; expanding aneurysm-screening programs, including Czechia's February 2025 national pilot; continuous technological advancement in low-profile and polymer-sealing graft design; and regulatory approvals and label expansions broadening indicated use.

Q5. Who are the major players in the aortic aneurysm stent grafts market?

The leading Aortic Aneurysm Stent Grafts companies in the market include - Medtronic, Terumo, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (MicroPort Scientific Corporation), Cook, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Endologix LLC, Lombard Medical, and LifeTech Scientific, among others.